BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31326996)

  • 21. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
    Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
    World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
    Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Takakura M; Shimizu M; Irabu H; Sakumura N; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Immunol; 2019 Nov; 208():108252. PubMed ID: 31449879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Lu M; Teng L; Xu Y; Xu X
    Pediatr Rheumatol Online J; 2023 Oct; 21(1):115. PubMed ID: 37828529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
    Schulert GS; Pickering AV; Do T; Dhakal S; Fall N; Schnell D; Medvedovic M; Salomonis N; Thornton S; Grom AA
    Ann Rheum Dis; 2021 May; 80(5):617-625. PubMed ID: 33277241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children.
    Mizuta M; Shimizu M; Irabu H; Usami M; Inoue N; Nakagishi Y; Wada T; Yachie A
    Rheumatology (Oxford); 2021 Jan; 60(1):231-238. PubMed ID: 32681176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of incomplete Kawasaki disease with extremely high serum ferritin and interleukin-18 levels.
    Noto T; Seto H; Fukuhara J; Murabayashi M; Yachie A; Ayusawa M; Morioka I
    BMC Pediatr; 2018 Dec; 18(1):386. PubMed ID: 30541507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Boom V; Anton J; Lahdenne P; Quartier P; Ravelli A; Wulffraat NM; Vastert SJ
    Pediatr Rheumatol Online J; 2015 Dec; 13():55. PubMed ID: 26634252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proceedings from the 2
    Canna SW; Schulert GS; de Jesus A; Pickering A; Brunner H; Gadina M; Levine S; Goldbach-Mansky R; Boutelle J; Sinha R; DeBenedetti F; Grom A;
    Pediatr Rheumatol Online J; 2020 Jul; 18(Suppl 1):53. PubMed ID: 32664935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers in Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Their Importance in COVID Era.
    Ailioaie LM; Ailioaie C; Litscher G
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
    Chen G; Deutsch GH; Schulert GS; Zheng H; Jang S; Trapnell B; Lee PY; Macaubas C; Ho K; Schneider C; Saper VE; de Jesus AA; Krasnow MA; Grom A; Goldbach-Mansky R; Khatri P; Mellins ED; Canna SW
    Arthritis Rheumatol; 2022 Jul; 74(7):1271-1283. PubMed ID: 35189047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
    Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Clin Exp Immunol; 2018 Mar; 191(3):349-355. PubMed ID: 28815559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
    Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
    Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of biomarkers for systemic juvenile idiopathic arthritis.
    Shenoi S; Ou JN; Ni C; Macaubas C; Gersuk VH; Wallace CA; Mellins ED; Stevens AM
    Pediatr Res; 2015 Nov; 78(5):554-9. PubMed ID: 26267155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Shimizu M; Nakagishi Y; Inoue N; Mizuta M; Ko G; Saikawa Y; Kubota T; Yamasaki Y; Takei S; Yachie A
    Clin Immunol; 2015 Oct; 160(2):277-81. PubMed ID: 26101092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
    Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
    Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels.
    Wakiguchi H; Hasegawa S; Hirano R; Kaneyasu H; Wakabayashi-Takahara M; Ohga S
    Pediatr Rheumatol Online J; 2015 Nov; 13():49. PubMed ID: 26581448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performances of the "MS-score" And "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.
    Sag E; Keskin A; Atalay E; Demir S; Cuceoglu MK; Akca UK; Batu ED; Bilginer Y; Ozen S
    Rheumatol Int; 2021 Jan; 41(1):87-93. PubMed ID: 33215249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
    Toplak N; Blazina Š; Avčin T
    Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.
    Ravelli A; Grom AA; Behrens EM; Cron RQ
    Genes Immun; 2012 Jun; 13(4):289-98. PubMed ID: 22418018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.